Solidigm Introduces PCIe 4.0 Solid-State Storage Drive: Solidigm™ P41 Plus
Solidigm has announced the Solidigm™ P41 Plus, the company’s first branded solid-state storage drive (SSD) since becoming a company in December 2021. The P41 Plus is an innovative PCIe 4.0 product that delivers the industry’s best combination of performance and value to PC users for everyday productivity and gaming.
Capable of delivering up to 4,125 MB/s sequential read speed, the Solidigm P41 Plus represents a breakthrough in cost efficiency, delivering great PCIe 4.0 performance at a price that won’t break the budget for everyday PC users.
The Solidigm P41 Plus features 144-layer 3D NAND and is available in an M.2 2280 form factor in capacities of 512GB, 1TB, and 2TB. For increased design flexibility, the Solidigm P41 Plus is also available to OEMs in 2230 and 2242 sizes from online and retail channels.
In a move that reinforces Solidigm’s commitment to being a new paradigm in solid-state storage, the company has invested significantly in storage software to unlock the best possible user experience. The result is Solidigm Synergy™ software, an optional but highly recommended suite that includes both a storage driver and a Windows application with robust drive health monitoring tools. The Solidigm Storage Driver supports host-managed caching by monitoring usage patterns to identify high-priority data, keeping the most important items in the cache, and enabling faster reads as the drive fills up. Solidigm Synergy software can be downloaded free of charge at solidigm.com.
“Whether playing the latest PC games, managing a business, or editing family photos, the Solidigm P41 Plus delivers performance that matters to end-users while delivering incredible value,” said Sanjay Talreja, General Manager, Client Products and Solutions Group. “Powered by innovative software, the Solidigm P41 Plus provides an exceptional combination of price and performance, in addition to a software-enhanced user experience, that makes our value proposition unique.”
The first product with the Solidigm™ brand, the P41 Plus highlights the company’s commitment to delivering an industry-leading portfolio of storage solutions that includes high-performance SSDs for the client, cloud, and data center markets. Visit solidigm.com for more information.
LEARN MORE
Solidigm is attending Flash Memory Summit, August 2-4, in Santa Clara, CA. We will be showcasing our innovative solutions at Booth 509. Webinars on the P41 will be held as follows:
North America: Wednesday, August 24, 2022, 10:30 a.m. PDT. Details
Europe: Wednesday, August 24, 2022 at 4 p.m. BST. Details
ABOUT SOLIDIGM
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Our origins reflect Intel’s longstanding innovation in memory products and SK hynix’s international leadership and scale in the semiconductor industry. Solidigm became a standalone U.S. subsidiary under SK hynix in December 2021. Headquartered in San Jose, CA, Solidigm is powered by the inventiveness of more than 2,000 employees in 20 locations around the world. For more, information about Solidigm, please visit solidigm.com and follow us on Twitter at @Solidigm and on LinkedIn.
All products, computer systems, dates, and figures specified are preliminary based on current expectations and are subject to change without notice.
Differences in hardware, software, or configuration will affect actual performance.
Solidigm optimizations, for Solidigm compilers or other products, may not optimize to the same degree for non-Solidigm products.
Solidigm technologies may require enabled hardware, software, or service activation. Nothing herein is intended to create any express or implied warranty.
The products described in this document may contain design defects or errors known as “errata,” which may cause the product to deviate from published specifications. Current characterized errata are available on request.
Your costs and results may vary.
© Solidigm. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp, (d/b/a Solidigm). Other names and brands may be claimed as the property of others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005060/en/
Contact information
Catherine Roberts
Keith Givens
press@solidigm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThinkPalm and RAD Join Forces to Deliver a Smart Business IoT Solution, Offering CSPs a Competitive Edge17.9.2025 10:00:00 EEST | Press release
ThinkPalm and RAD have partnered to integrate NetvirE, ThinkPalm’s advanced IIoT platform, and RAD’s Smart Business IoT solution to enable smarter industrial operations. This collaboration gives Communication Service Providers (CSPs) a competitive edge in digital transformation, remote asset management, and IoT services. 360°, End-to-End IoT Offering The Smart Business IoT solution combines advanced IoT gateways, smart sensors, and intelligent dashboards into one integrated system. It delivers real-time, historical, and AI-driven insights for remote monitoring, predictive maintenance, and activity detection, enabling CSPs to move beyond SIM-based plans and offer high-value, integrated solutions for smarter asset decisions without requiring IT expertise. Expanding CSP Horizons in the UK and Europe For CSPs in competitive markets like the UK and Europe, ThinkPalm’s expertise combined with RAD's industry leadership offers an unparalleled advantage. Together, they deliver secure, tailored
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 09:57:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting new data across its broad portfolio of dermatological treatments including new real-world data of lebrikizumab on atopic dermatitis, new clinical data of tildrakizumab on psoriasis and tirbanibulin on actinic keratosis. The 34th EADV congress will take place from September 17 to 20 in Paris, France. At the congress, Almirall contributes a total of 44 scientific abstracts focused on advancing patient care across the company’s broad portfolio of dermatological treatments including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa. With a strong emphasis on real-world evidence, patient-reported outcomes, and well-being, Almirall’s scientific programme includes multiple presentations, two expert-led symposia on psoriasis and atopic dermatitis, and an interactive exh
SES delivered unprecedented MEO satellite connectivity for French Navy’s Clemenceau 25 mission17.9.2025 09:50:00 EEST | Press release
SES announced today that the French Navy’s aircraft carrier Charles de Gaulle leveraged its secure and reliable O3b mPOWER satcom service – Managed Naval mPOWERED – during the Clemenceau 25 mission. This high-throughput, low-latency Medium Earth Orbit (MEO) connectivity solution supported all of the aircraft carrier’s operations, while facilitating collaboration with mission partners. During the five-month deployment, the French Carrier Strike Group (GAN) covered 40,000 nautical miles and conducted various exercises and joint activities with around twenty allied nations. The connectivity provided by SES ensured optimal performance and uninterrupted operational availability for the aircraft carrier’s mission-critical applications. Thanks to the global reach, reliability and exceptional high-speed capacity of the Managed Naval mPOWERED solution, which can deliver several hundred Mb/s of guaranteed throughput, the Charles de Gaulle aircraft carrier enjoyed continuous connectivity througho
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 09:00:00 EEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 08:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support the planned regulatory submissions for povorcitinib in HS in Europe and the United States in 2025 and early 2026, respectively. The presentation will take place today at 2:45 p.m. CEST during a late-breaking oral presentation (Session: Late Breaking News; Presentation ID D1T01.1C) at the European Association of Dermatology and Venereology (EADV) 2025 Congress. “HS remains a challenging and often debilitating condition and many patients are in need of new, well-tolerated and effective therapies that address prominent signs and symptoms of the disease, including inflammatory lesions and pain,” said Pablo J. Cagnoni, M.D., President and Head of Res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom